UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Volltextzugriff (PDF)

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008, Vol.4 (5), p.731-733

Karantza, Vassiliki

2008

Volltextzugriff (PDF)

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008-07, Vol.4 (5), p.731-733

Karantza, Vassiliki

2008

Volltextzugriff (PDF)

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008-07, Vol.4 (5), p.731

Karantza, Vassiliki

2008

Volltextzugriff (PDF)

Abstract 3513: Hydroxychoroquine (HCQ) modulates autophagy in melanoma: preliminary results of a phase 0 trial in patients with resectable melanoma

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3513-3513

2013

Volltextzugriff (PDF)

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3545-3545

2011

Volltextzugriff (PDF)

Abstract 3777: Autophagy and HER2 interaction in mammary tumorigenesis

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3777-3777

2011

Volltextzugriff (PDF)

Abstract 4261: Prospective next generation sequencing (NGS) of rare or poor prognosis cancers

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4261-4261

2014

Volltextzugriff (PDF)

Abstract A004: Expansion of immature mammary epithelial populations promotes Wnt1 -driven mammary tumorigenesis in an autophagy-deficient mouse model

Molecular cancer research, 2013-10, Vol.11 (10_Supplement), p.A004-A004

2013

Volltextzugriff (PDF)

Abstract CN05-02: Autophagy and mammary tumorigenesis: role of metabolic and ER stress management

Cancer prevention research (Philadelphia, Pa.), 2008-11, Vol.1 (7_Supplement), p.CN05-02-CN05-02

Karantza-Wadsworth, Vassiliki

2008

Volltextzugriff (PDF)

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Volltextzugriff (PDF)

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Volltextzugriff (PDF)

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.GS01-02-GS01-02

2024

Volltextzugriff (PDF)

Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.GS01-05-GS01-05

2024

Volltextzugriff (PDF)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Volltextzugriff (PDF)

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-01-GS3-01

2021

Volltextzugriff (PDF)

Abstract LB-138: Autophagy regulator BECN1 acts as a context-dependent tumor suppressor opposing parity-associated and WNT1-driven mammary tumorigenesis

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-138-LB-138

2014

Volltextzugriff (PDF)

Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-225-LB-225

2019

Volltextzugriff (PDF)

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Volltextzugriff (PDF)

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-09-05

2020

Volltextzugriff (PDF)

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-04-PD14-04

2021

Volltextzugriff (PDF)

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-07-PD14-07

2021

Volltextzugriff (PDF)

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Volltextzugriff (PDF)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(93)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Abstract 3513: Hydroxychoroquine (HCQ) modulates autophagy in melanoma: preliminary results of a phase 0 trial in patients with resectable melanoma

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Abstract 3777: Autophagy and HER2 interaction in mammary tumorigenesis

Abstract 4261: Prospective next generation sequencing (NGS) of rare or poor prognosis cancers

Abstract A004: Expansion of immature mammary epithelial populations promotes Wnt1 -driven mammary tumorigenesis in an autophagy-deficient mouse model

Abstract CN05-02: Autophagy and mammary tumorigenesis: role of metabolic and ER stress management

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract LB-138: Autophagy regulator BECN1 acts as a context-dependent tumor suppressor opposing parity-associated and WNT1-driven mammary tumorigenesis

Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Aktive Filter

Suchergebnisse filtern